col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

160 Results       Page 1

Wiley: British Journal of Dermatology
  original article Date Title Authors   All Authors
1 [GO] 2022―Feb―01 Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey Katie Bechman, Emma S. Cook, Nick Dand, Zenas Z.N. Yiu, Teresa Tsakok, Freya Meynell, et al. (+33)
2 [GO] 2022―Jan―27 Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients Haig Pakhchanian, Rahul Raiker, Melanie Wolf, Shannon C. Trotter
3 [GO] 2022―Jan―06 Do treatments for psoriasis increase the risk of hospital admission or death caused by COVID-19 infections?
4 [GO] 2022―Jan―06 Varied skin reactions after COVID-19 vaccination
5 [GO] 2021―Dec―17 Chilblain-like lesions during the COVID-19 outbreak
6 [GO] 2021―Nov―29 COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation M. Kasperkiewicz, R. Strong, K. Mead, M. Yale, D. Zillikens, D.T. Woodley, A. Recke
7 [GO] 2021―Nov―25 Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine T. Žagar, N. Hlača, I. Brajac, L. Prpić-Massari, S. Peternel, M. Kaštelan
8 [GO] 2021―Nov―13 Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies T. Gambichler, N. Hamdani, H. Budde, M. Sieme, M. Skrygan, L. Scholl, et al. (+10)
9 [GO] 2021―Nov―08 Should we look beyond the interferon signature in chilblain-like lesions associated with COVID-19? S.M. Pilkington, R.E.B. Watson
10 [GO] 2021―Nov―02 Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic S. Cazzaniga, L. Naldi
11 [GO] 2021―Nov―02 COVID-19 vaccines and skin manifestations V. Bataille, S. Puig
12 [GO] 2021―Nov―02 Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination T. Gambichler, C. Krogias, I. Tischoff, A. Tannapfel, R. Gold, L. Susok
13 [GO] 2021―Oct―08 Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak L. Frumholtz, J.-D. Bouaziz, M. Battistella, J. Hadjadj, R. Chocron, D. Bengoufa, et al. (+24)
14 [GO] 2021―Oct―06 Occupational dermatoses during the second COVID-19 pandemic wave: a UK prospective study of 805 healthcare workers J. M. Gao, R. Goiriz, S. Rajpopat, P. Goldsmith
15 [GO] 2021―Sep―29 A case of COVID-19 vaccination-associated forme fruste purpura fulminans J. Griss, S. Eichinger, S. Winkler, W. Weninger, P. Petzelbauer
16 [GO] 2021―Aug―24 Not relevant responses in the era of Covid-19 - are we underestimating dermatology life quality index values? N. Kearney, R. Hambly, A. Alsharqi, B. Kirby
17 [GO] 2021―Aug―16 Sunlight separately from vitamin D is associated with a lower risk of death from COVID-19
18 [GO] 2021―Jul―26 Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1,326,312 patients in France L. Penso, R. Dray-Spira, A. Weill, M. Zureik, E. Sbidian
19 [GO] 2021―Jul―14 Analysis of T cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in chilblain-like lesions patients during the COVID-19 pandemic C. Cassius, M. Merandet, L. Frumholtz, D. Bergerat, A. Samri, C. Grolleau, et al. (+10)
20 [GO] 2021―Jul―13 Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases A. Català, C. Muñoz-Santos, C. Galván-Casas, M. Roncero Riesco, D. Revilla Nebreda, A. Solá-Truyols, et al. (+34)
21 [GO] 2021―Jul―06 GIRFT06: Dermatology high-cost drug management: pharmacists getting it right first time in COVID-19
22 [GO] 2021―Jul―06 DS26: COVID-19 and reduced detection of malignant melanoma in secondary dermatology services
23 [GO] 2021―Jul―06 DT04: Pandemic placement: delivering the dermatology undergraduate curriculum at a UK medical school during the COVID-19 crisis
24 [GO] 2021―Jul―06 BT10: Medical education in the COVID-19 era: a remote dermatology attachment
25 [GO] 2021―Jul―06 DS06: Contending with COVID-19 in a Mohs micrographic surgery service
26 [GO] 2021―Jul―06 P19: Cutaneous manifestations of COVID-19 in the UK: a registry of digital submissions from interdisciplinary healthcare professionals
27 [GO] 2021―Jul―06 DP16: Severe, ulcerative cold panniculitis following COVID-19 infection
28 [GO] 2021―Jul―06 DP08: Leprosy unmasked by COVID-19 infection: a new diagnosis of leprosy with development of type 1 reversal reaction
29 [GO] 2021―Jul―06 DS25: Pandemic pressures: the impact of COVID-19 on the 2-week-wait service at a regional skin oncology centre
30 [GO] 2021―Jul―06 P28: The effects of COVID-19 on undergraduate dermatology training: a qualitative study
31 [GO] 2021―Jul―06 BT19: The use of a novel teledermatology/teledermoscopy service to maintain a dermatology cancer service in the midst of the COVID-19 pandemic
32 [GO] 2021―Jul―06 BT18: A new era for teledermatology in the COVID-19 pandemic
33 [GO] 2021―Jul―06 BT16: Disaster-recovery modelling to shape services: a dermatology helpline as a telemedicine intervention during the initial surge of the COVID-19 pandemic
34 [GO] 2021―Jul―06 PD11: Access to phototherapy during the COVID-19 pandemic
35 [GO] 2021―Jul―06 BT14: Exploring the feasibility of a remote acne service: a report of a pilot study using the MySkinSelfie platform during the COVID-19 pandemic
36 [GO] 2021―Jul―06 BT09: Standard of patient-sent images in teledermatology 2-week-wait skin cancer clinics during the COVID-19 pandemic
37 [GO] 2021―Jul―06 BI08: Remote management of immunotherapy-induced bullous pemphigoid during the COVID-19 pandemic
38 [GO] 2021―Jul―06 DS14: Experience of using a scar-assessment tool to evaluate scars after Mohs surgery via virtual consultation during the COVID-19 pandemic
39 [GO] 2021―Jul―06 P57: Surprising trends in the detection of cutaneous malignancy during the COVID-19 pandemic
40 [GO] 2021―Jul―06 BT15: Evaluating paediatric dermatology telephone clinics during the COVID-19 pandemic in a UK cohort: a prospective study
41 [GO] 2021―Jul―06 DS23: A multicentre qualitative study of patients’ experience of skin surgery during the COVID-19 pandemic in the UK
42 [GO] 2021―Jul―06 DT07: The impact of the COVID-19 pandemic on dermatology ST3 application preparation: a national survey of junior doctors in the UK
43 [GO] 2021―Jul―06 BI07: The effect of the COVID-19 pandemic on immunosuppressed patients undergoing skin surveillance
44 [GO] 2021―Jul―06 O01: The impact of the COVID-19 pandemic on people with psoriasis: findings from a global patient-reported registry
45 [GO] 2021―Jul―06 P25: The impact of the second wave of the COVID-19 pandemic on the quality of life of patients with skin cancer
46 [GO] 2021―Jul―06 CD08: Occupational dermatoses during the second COVID-19 pandemic wave: an audit of 401 healthcare workers
47 [GO] 2021―Jul―06 P38: Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting
48 [GO] 2021―Jul―06 PS06 (P38): Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting
49 [GO] 2021―Jul―06 BT12: The environmental impact of teledermatology in the COVID-19 pandemic: a silver lining
50 [GO] 2021―Jul―06 CD07: A survey of the incidence of skin problems in a cohort of hospital staff during the COVID-19 pandemic: can this help plan future services?
51 [GO] 2021―Jul―06 DT03: Diversifying educational resources during the COVID-19 pandemic: delivering educational dermatology podcasts and webinars for healthcare professionals
52 [GO] 2021―Jul―06 BT04: A new virtual inpatient dermatology electronic referral service: a timely answer to reducing cross-contamination during the COVID-19 pandemic?
53 [GO] 2021―Jul―06 DT02: What has been the impact of COVID-19 redeployment on dermatology trainees’ professional identity? An interpretative phenomenological study
54 [GO] 2021―Jul―06 P21: Practising dermatology in the era of COVID-19: a tertiary centre’s experience of adapting to change
55 [GO] 2021―Jul―06 PD14: Treating field cancerization in a time of COVID-19: daylight photodynamic therapy is effective, socially distant and satisfactory to our most vulnerable patients
56 [GO] 2021―Jul―06 P46: Occupational dermatoses during COVID-19: effect on work and wellbeing
57 [GO] 2021―Jul―06 P62: An increase in Breslow thickness: coronavirus or coincidence?
58 [GO] 2021―Jul―06 PD05: Skin safety and efficacy of filtered far ultraviolet C for SARS-CoV-2 inactivation
59 [GO] 2021―Jul―06 CD09: A review of semi-virtual patch testing during the SARS-CoV-2 pandemic: practicalities and patient experience
60 [GO] 2021―Jul―06 Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination T. Gambichler, S. Boms, S. Hessam, I. Tischoff, A. Tannapfel, T. Lüttringhaus, et al. (+2)
61 [GO] 2021―Jul―06 P24: Dermatology medical student history taking via the telephone: a way to minimize disruption to medical education, particularly during a pandemic
62 [GO] 2021―Jul―06 P73: A novel approach to systemic monitoring in a pandemic
63 [GO] 2021―Jul―05 Yet another benefit from sunlight in the fight against COVID-19? R.L. McKenzie, J.B. Liley
64 [GO] 2021―Jul―03 在 2019 年新型冠状病毒疾病 (COVID-19) 疫情期间, 银屑病或关节病患者的隔离因治疗类型而异
65 [GO] 2021―Jul―03 Shielding behaviour in people with psoriasis or a joint condition during the COVID-19 pandemic differs by treatment type
66 [GO] 2021―Jun―15 Relapse of chilblain-like lesions during the second COVID-19 pandemic wave: a cohort follow-up T. Hubiche, F. Le Duff, E. Fontas, J. Rapp, C. Chiaverini, T. Passeron
67 [GO] 2021―Jun―11 Kawasaki-like Multisystem Inflammatory Syndrome Associated with Coronavirus disease 2019 in an Adult: A case report R. Dabas, G. Varadaraj, S. Sandhu, A. Bhatnagar, R. Pal
68 [GO] 2021―Jun―09 COVID-19 outcomes in patients with autoimmune blistering disease E. Hwang, M.M. Tomayko
69 [GO] 2021―May―25 COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations M. Razmi T, T.P. Afra, T.P. Mohammed, P.T.M. Ashik, E. Sukesh
70 [GO] 2021―May―20 Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health W.H. Bermingham, M.R. Ardern-Jones, A.P. Huissoon, M.T. Krishna
71 [GO] 2021―May―19 Skin checks and skin cancer diagnosis in Australian general practice before and during the COVID pandemic, 2011-2020 J. Roseleur, D.A. Gonzalez-Chica, J. Emery, N.P. Stocks
72 [GO] 2021―May―17 Rarity of cutaneous findings among asymptomatic to mildly symptomatic COVID-19 patients admitted to a COVID Care facility in Delhi, India: An observational study A. Khurana, A. Mittal, R. Jain, A. Mishra, S.R. Mathachan
73 [GO] 2021―May―13 Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease A. Al-Janabi, Z. Littlewood, C.E.M. Griffiths, H.J.A. Hunter, H. Chinoy, C. Moriarty, et al. (+2)
74 [GO] 2021―May―07 SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study C. Nguyen, K. Yale, F. Casale, A. Ghigi, K. Zheng, J.I. Silverberg, N.A. Mesinkovska
75 [GO] 2021―May―06 Psoriasis, COVID-19 and shielding G. Becher, A.D. Burden
76 [GO] 2021―May―05 Diagnosis of COVID-19 using skin rashes
77 [GO] 2021―May―03 The impact of the COVID-19 pandemic on skin cancer incidence and treatment in England, 2020 Z.C. Venables, S. Ahmed, T. Bleiker, J. Broggio, M. Kwiatkowska, N.J. Levell, et al. (+6)
78 [GO] 2021―Apr―27 Chilblain lesions after COVID-19 mRNA vaccine A. Pileri, A. Guglielmo, B. Raone, A. Patrizi
79 [GO] 2021―Apr―27 Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination A.M. Carballido Vázquez, B. Morgado
80 [GO] 2021―Apr―24 Pernio after COVID-19 Vaccination S. Lopez, P. Vakharia, T. Vandergriff, E.E. Freeman, R. Vasquez
81 [GO] 2021―Apr―10 Outcomes of COVID-19 in Patients with Skin Cancer R. Raiker, H. Pakhchanian, A. Hussain, M. Deng
82 [GO] 2021―Apr―09 Ultraviolet A Radiation and COVID-19 Deaths in the USA with replication studies in England and Italy M. Cherrie, T. Clemens, C. Colandrea, Z. Feng, D.J. Webb, R.B. Weller, C. Dibben
83 [GO] 2021―Mar―18 Recurrence of chilblains during a second contact with SARS-CoV-2: a case report S. Maanaoui, F. Salez, O. Carpentier
84 [GO] 2021―Mar―17 Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study Z.Z.N. Yiu, G. Harding, C.E.M. Griffiths, R.B. Warren, E. McMullen, H.J.A. Hunter
85 [GO] 2021―Mar―04 The skin as a target for SARS-CoV-2 infection: exploiting the web for suitable data L. Naldi
86 [GO] 2021―Mar―03 Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic E.E. Freeman, D.E. McMahon, J.B. Lipoff, M. Rosenbach, S.R. Desai, M. Fassett, et al. (+4)
87 [GO] 2021―Feb―20 Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision E. Sotiriou, K. Bakirtzi, I. Papadimitriou, E. Paschou, E. Vakirlis, A. Lallas, D. Ioannides
88 [GO] 2021―Feb―08 COVID-19 相关的皮肤疾病以及相关生物制剂
89 [GO] 2021―Feb―08 Association of COVID-19 with skin diseases and relevant biologics
90 [GO] 2021―Jan―29 SARS-CoV-2 Spike Protein Positivity in Pityriasis Rosea-like and Urticaria-like Rashes of COVID-19 E. Welsh, J.A. Cardenas-de la Garza, A. Cuellar-Barboza, R. Franco-Marquez, R.I. Arvizu-Rivera
91 [GO] 2021―Jan―17 Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality? C. Bernigaud, D. Guillemot, A. Ahmed-Belkacem, L. Grimaldi-Bensouda, A. Lespine, F. Berry, et al. (+6)
92 [GO] 2021―Jan―15 Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection A. Visconti, V. Bataille, N. Rossi, J. Kluk, R. Murphy, S. Puig, et al. (+9)
93 [GO] 2021―Jan―14 COVID-19-associated cutaneous manifestations: does HHV-6 play an etiological role? I. Abadías-Granado, A. Navarro-Bielsa, A.M. Morales-Callaghan, L. Roc, C.C. Suso-Estívalez, M. Povar-Echeverría, Y. Gilaberte
94 [GO] 2021―Jan―10 COVID-19 related dermatosis in November 2019. Could this case be Italy’s patient zero? R. Gianotti, M. Barberis, G. Fellegara, C. Galván-Casas, E. Gianotti
95 [GO] 2020―Dec―24 Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey S.K. Mahil, M. Yates, S.M. Langan, Z.Z.N. Yiu, T. Tsakok, N. Dand, et al. (+37)
96 [GO] 2020―Dec―16 SARS-CoV-2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions: reply from the authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo
97 [GO] 2020―Dec―10 Response to Tembhre et al.: ‘Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2’ J.R. Gehlhausen, C.J. Ko, W. Damsky
98 [GO] 2020―Dec―04 Association of skin diseases, biological treatment and COVID-19 during the first wave of the pandemic M.A. Descalzo, I. Garcia-Doval
99 [GO] 2020―Nov―29 Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window D. Bessis
100 [GO] 2020―Nov―06 Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2 M.K. Tembhre, A.S. Parihar, V.K. Sharma, S. Imran, N. Bhari, R. Lakshmy, A. Bhalla
101 [GO] 2020―Nov―05 Response to “Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic G. Murray, D. Roche, A. Ridge, C. Hackett, A.M. Tobin
102 [GO] 2020―Nov―03 Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein C.D. Soares, A. Mosqueda-Taylor, M.G.F. Carvalho, O.P. Almeida
103 [GO] 2020―Nov―02 COVID-19 疫情期间观察到的大多数冻疮与 COVID-19 感染无关
104 [GO] 2020―Nov―02 Most chilblains observed during the COVID-19 outbreak are not linked to COVID-19 infection
105 [GO] 2020―Oct―28 Occupational dermatoses during the Covid-19 pandemic: a multicentre audit in the UK and Ireland H. O’Neill, I. Narang, D.A. Buckley, T.A. Phillips, C.G. Bertram, T.O. Bleiker, et al. (+9)
106 [GO] 2020―Oct―26 Prurigo pigmentosa and new-onset type 1 diabetes in a black female patient testing positive for SARS-CoV-2 IgG K.M. Derrick, D.R. Mazori, E.R. Heilman, S.A. Glick
107 [GO] 2020―Oct―05 SARS-CoV-2 导致冠状病毒脚趾
108 [GO] 2020―Oct―05 SARS-CoV-2 causes Covid Toes
109 [GO] 2020―Oct―01 SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions: reply from authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo
110 [GO] 2020―Oct―01 SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions J.K. Brealey, S.E. Miller
111 [GO] 2020―Sep―25 Response to ‘No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain’. Reply from the authors D. Caselli, M. Chironna, D. Loconsole, M. Aricò
112 [GO] 2020―Sep―24 Prevalence of mucocutaneous manifestations, oral and palmoplantar findings in 666 patients with COVID-19 in a field hospital in Spain A. Nuno-Gonzalez, P. Martin-Carrillo, K. Magaletsky, M.D. Martin Rios, C. Herranz Mañas, J. Artigas Almazan, et al. (+11)
113 [GO] 2020―Sep―03 A review of studies into skin symptoms of COVID-19
114 [GO] 2020―Sep―03 COVID-19 皮肤症状研究综述
115 [GO] 2020―Sep―02 Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea S.I. Cho, Y.E. Kim, S.J. Jo
116 [GO] 2020―Sep―01 COVID-19 Session
117 [GO] 2020―Sep―01 Illuminating, through immunohistochemistry, the link between SARS-CoV-2 and pernio (chilblains) D.A. Wetter
118 [GO] 2020―Aug―31 Paucity of COVID-19 Dermatology Literature from Low- and Middle-Income Countries R.S. Pendse, B.L. Schwartz, J.L. Jia, E.E. Bailey
119 [GO] 2020―Aug―28 COVID-19 in hidradenitis suppurativa patients X.T. Lima, M.A. Cueva, M.B. Alora
120 [GO] 2020―Aug―28 Response to “No evidence of SARS-CoV-2 infection by PCR or serology in children with pseudochilblain” S. Recalcati, S. Tonolo, F. Luzzaro, F. Fantini
121 [GO] 2020―Aug―15 Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned M. Baeck, D. Hoton, L. Marot, A. Herman
122 [GO] 2020―Aug―15 Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned: reply from authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez-Peralto, L. Requena, A. Torrelo
123 [GO] 2020―Aug―13 Co-Reactivation of Human Herpesvirus alpha Subfamily (HSV Ⅰ and VZV) in Critically Ill Patient with COVID-19 R. Xu, Y. Zhou, L. Cai, L. Wang, J. Han, X. Yang, et al. (+4)
124 [GO] 2020―Aug―13 Occupational Dermatology in the time of the Covid-19 pandemic: A report of experience from London and Manchester, United Kingdom F.J. Ferguson, G. Street, L. Cunningham, I.R. White, J.P. McFadden, J. Williams
125 [GO] 2020―Aug―13 Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains G. Battesti, V. Descamps Vincent
126 [GO] 2020―Aug―13 Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains: reply from authors L. Le Cleach, S. Fourati, E. Sbidian, M. Beylot-Barry
127 [GO] 2020―Jul―31 Cutaneous signs in SARS CoV-2 infection: A plea for more rigorous peer-review in the time of COVID-19 H. Kittler, P. Tschandl, W. Weninger
128 [GO] 2020―Jul―23 A Very Peculiar Practice: Dermatology in the era of Covid-19 S. Walsh, D. Creamer
129 [GO] 2020―Jul―22 The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series C. Magro, J.J. Mulvey, J. Laurence, S. Sanders, N. Crowson, M. Grossman, et al. (+2)
130 [GO] 2020―Jul―22 High incidence of hand eczema in Danish school children following intensive hand hygiene during the COVID-19 pandemic - a nationwide questionnaire study A.B. Simonsen, I.F. Ruge, A.S. Q꫞, J.D. Johansen, J.P. Thyssen, C. Zachariae
131 [GO] 2020―Jul―06 Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on PCR and serology testing L. Le Cleach, L. Dousset, H. Assier, S. Fourati, S. Barbarot, C. Boulard, et al. (+15)
132 [GO] 2020―Jul―02 Identificadas las principales manifestaciones en la piel de la COVID-19
133 [GO] 2020―Jul―02 COVID-19 确诊患者的五种常见皮肤表现
134 [GO] 2020―Jul―02 Response to: “Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases”: Vesicular eruption in COVID-19 - to exclude varicella S.Y.D. Lim, H.L. Tey
135 [GO] 2020―Jul―02 “Vesicular eruption in COVID-19 - to exclude varicella”: reply from the authors A. Català, C. Galván Casas, G. Carretero Hernández, I. García-Doval
136 [GO] 2020―Jul―02 Five common skin manifestations of COVID-19 identified
137 [GO] 2020―Jul―02 Chilblain-like lesions during COVID-19 pandemic: a serological study on a case series L. Rizzoli, L. Collini, M. Magnano, S. Termine, R. Barcelli, S.D. Infusino, et al. (+4)
138 [GO] 2020―Jul―02 No evidence of SARS-Cov-2 infection by PCR or serology in children with pseudochilblain D. Caselli, M. Chironna, D. Loconsole, L. Nigri, F. Mazzotta, D. Bonamonte, M. Aricò
139 [GO] 2020―Jun―29 Global Hidradenitis Suppurativa COVID-19 Registry: A Registry to Inform Data-Driven Management Practices H.B. Naik, R. Alhusayen, J. Frew, S. Guilbault, J.R. Ingram, M.A. Lowes, et al. (+4)
140 [GO] 2020―Jun―25 COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a PCR-negative patient C. Santonja, F. Heras, L. Núñez, L. Requena
141 [GO] 2020―Jun―22 Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from authors C. Galván-Casas, A. Catalá, G. Carretero Hernández, I. Garcia-Doval
142 [GO] 2020―Jun―20 SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases I. Colmenero, C. Santonja, M. Alonso-Riaño, L. Noguera-Morel, A. Hernández-Martín, D. Andina, et al. (+4)
143 [GO] 2020―Jun―17 SARS-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from the authors C. Galván Casas, A. Català, G. Carretero Hernández, I. García-Doval
144 [GO] 2020―Jun―15 Risk of infections in psoriasis. A lesson to learn during the SARS -CoV-2 pandemic L. Naldi
145 [GO] 2020―Jun―13 Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations F. Drago, G. Ciccarese, A. Rebora, S.I. Muzic, A. Parodi
146 [GO] 2020―Jun―05 Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic C.H. Earnshaw, H.J.A. Hunter, E. McMullen, C.E.M. Griffiths, R.B. Warren
147 [GO] 2020―Jun―01 Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy A. Carugno, P. Sena, F. Raponi, E. Robustelli Test, P. Vezzoli
148 [GO] 2020―Jun―01 Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue A.V. Marzano, N. Cassano, G. Genovese, C. Moltrasio, G.A. Vena
149 [GO] 2020―Jun―01 Emergency management of 2019 novel coronavirus: implications for the dermatology department J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man
150 [GO] 2020―May―29 Absence of Skin of Colour Images in Publications of COVID-19 Skin Manifestations J.C. Lester, J.L. Jia, L. Zhang, G.A. Okoye, E. Linos
151 [GO] 2020―May―29 Virtual melanoma checks during a pandemic M. Janda, S.M. Swetter, C. Horsham, H.P. Soyer
152 [GO] 2020―May―27 Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection M. Hughes, S. Rogers, G. Lepri, C. Bruni, M. Matucci-Cerinic
153 [GO] 2020―May―14 Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient M. Llamas-Velasco, P. Muñoz-Hernández, J. Lázaro-González, A. Reolid-Pérez, B. Abad-Santamaría, J. Fraga, E. Daudén-Tello
154 [GO] 2020―Apr―30 Cutaneous lesions in a patient with COVID-19: are they related? B. Ahouach, S. Harant, A. Ullmer, P. Martres, E. Bégon, L. Blum, et al. (+2)
155 [GO] 2020―Apr―29 Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic S.K. Mahil, Z.Z.N. Yiu, K.J. Mason, N. Dand, B. Coker, D. Wall, et al. (+16)
156 [GO] 2020―Apr―29 Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases C. Galván Casas, A. Català, G. Carretero Hernández, P. Rodríguez-Jiménez, D. Fernández Nieto, A. Rodríguez-Villa Lario, et al. (+19)
157 [GO] 2020―Apr―28 The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience P. Gisondi, P. Facheris, P. Dapavo, S. Piaserico, A. Conti, L. Naldi, et al. (+3)
158 [GO] 2020―Apr―17 Phototherapeutic approach to dermatological patients during the 2019 Coronavirus pandemic: Real-life Data from the Italian Red Zone A. Pacifico, M. Ardigò, P. Frascione, G. Damiani, A. Morrone
159 [GO] 2020―Apr―07 Adverse Skin Reactions Among Healthcare Workers During the Coronavirus Disease 2019 Outbreak: A Survey in Wuhan and Its Surrounding Regions P. Lin, S. Zhu, Y. Huang, L. Li, J. Tao, T. Lei, et al. (+17)
160 [GO] 2020―Mar―06 Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man

160 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.021 sec